Abstract
Despite an extraordinary investment in R the yield of successful new drugs has been disproportionately low in recent years, suggesting that the whole process of drug development requires rethinking and reform. Most analyses on this issue focus on molecular target discovery considerations. Target identification is characterized by a surplus of potential targets, but there is a translational bottleneck primarily due to limitations of currently employed target validation platforms. Meanwhile, the clinical entities, to which treatments are directed, are also highly complex in terms of pathophysiologic mechanisms and manifestations. In the present study we discuss the limitations of current molecular target discovery approaches mainly in regard to selectivity and efficacy. We also describe the constraints imposed on drug development by the current diagnostic constructs and the tendency towards dissecting the complex clinical phenotypes to component intermediate phenotypes. Finally, we describe how the reconsideration of molecular and clinical targets in polygenic diseases may lead to new strategies of pharmacological intervention directed against component dysfunctions, rather than the whole complex phenotype. Such strategies involve the combination of single ligands that act selectively on multiple molecules involved in a particular disease, or the employment of “multi-targeted” drugs, i.e. single drug molecules that hit selectively multiple receptors sharing common binding sites.
Keywords: Systemic evaluation of ligands by exponential enrichment, High throughput screening, Acute respiratory distress syndrome, Multiple organ distress syndrome, Extracellular signal-regulated kinase, Human genome program
Current Topics in Medicinal Chemistry
Title: Rethinking Target Discovery in Polygenic Diseases
Volume: 6 Issue: 16
Author(s): Christodoulos S. Flordellis, Antonis S. Manolis, Herve Paris and Andreas Karabinis
Affiliation:
Keywords: Systemic evaluation of ligands by exponential enrichment, High throughput screening, Acute respiratory distress syndrome, Multiple organ distress syndrome, Extracellular signal-regulated kinase, Human genome program
Abstract: Despite an extraordinary investment in R the yield of successful new drugs has been disproportionately low in recent years, suggesting that the whole process of drug development requires rethinking and reform. Most analyses on this issue focus on molecular target discovery considerations. Target identification is characterized by a surplus of potential targets, but there is a translational bottleneck primarily due to limitations of currently employed target validation platforms. Meanwhile, the clinical entities, to which treatments are directed, are also highly complex in terms of pathophysiologic mechanisms and manifestations. In the present study we discuss the limitations of current molecular target discovery approaches mainly in regard to selectivity and efficacy. We also describe the constraints imposed on drug development by the current diagnostic constructs and the tendency towards dissecting the complex clinical phenotypes to component intermediate phenotypes. Finally, we describe how the reconsideration of molecular and clinical targets in polygenic diseases may lead to new strategies of pharmacological intervention directed against component dysfunctions, rather than the whole complex phenotype. Such strategies involve the combination of single ligands that act selectively on multiple molecules involved in a particular disease, or the employment of “multi-targeted” drugs, i.e. single drug molecules that hit selectively multiple receptors sharing common binding sites.
Export Options
About this article
Cite this article as:
Flordellis S. Christodoulos, Manolis S. Antonis, Paris Herve and Karabinis Andreas, Rethinking Target Discovery in Polygenic Diseases, Current Topics in Medicinal Chemistry 2006; 6 (16) . https://dx.doi.org/10.2174/156802606778194226
DOI https://dx.doi.org/10.2174/156802606778194226 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ruthenium as an Effective Nitric Oxide Scavenger
Current Topics in Medicinal Chemistry Allosteric Modulation of Protease-Activated Receptor Signaling
Mini-Reviews in Medicinal Chemistry The Impact of microRNAs in Breast Cancer Angiogenesis and Progression
MicroRNA Coumarins as Potential Anti-drug Resistant Cancer Agents: A Mini Review
Current Topics in Medicinal Chemistry Spirulina paltensis: Food and Function
Current Nutrition & Food Science 2D, 3D, G-QSAR and Docking Studies of Thiazolyl-pyrazoline Analogues as Potent (Epidermal Growth Factor Receptor-tyrosine Kinase) EGFR-TK Inhibitors
Letters in Drug Design & Discovery Identification and Usage of Fluorescent Probes as Nanoparticle Contrast Agents in Detecting Cancer
Current Pharmaceutical Design Immunogenicity and Tumorigenicity of Pluripotent Stem Cells and their Derivatives: Genetic and Epigenetic Perspectives
Current Stem Cell Research & Therapy Array-Based Approaches for the Identification of Epigenetic Silenced Tumor Suppressor Genes
Current Genomics Overexpression of RAD50 is the Marker of Poor Prognosis and Drug Resistance in Breast Cancer Patients
Current Cancer Drug Targets Targeting of Cancer-Related Proteins with PNA Oligomers
Current Cancer Drug Targets Thrombomodulin – A New Target for Treating Stroke at the Crossroad of Coagulation and Inflammation
Current Medicinal Chemistry Ethanolic Extract of Berberis Vulgaris Fruits Inhibits the Proliferation of MCF-7 Breast Cancer Cell Line Through Induction of Apoptosis
Infectious Disorders - Drug Targets Viral Vectors for Gene-Directed Enzyme Prodrug Therapy
Current Gene Therapy Oxidative Stress in the Cochlea: An Update
Current Medicinal Chemistry Development of Fourth Generation ABC Inhibitors from Natural Products: A Novel Approach to Overcome Cancer Multidrug Resistance
Anti-Cancer Agents in Medicinal Chemistry Hypoxia Helps Glioma to Fight Therapy
Current Cancer Drug Targets Reprofiling of Troglitazone Towards More Active and Less Toxic Derivatives: A New Hope for Cancer Treatment?
Current Topics in Medicinal Chemistry Mucosal Healing in Crohn’s Disease: Relevance for Clinical Outcomes
Current Drug Targets Feature Clustering and Ensemble Learning Based Approach for Software Defect Prediction
Recent Advances in Computer Science and Communications